Posts Tagged ‘ribavirin’

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV

Posted by • May 16th, 2014

In previously untreated patients with HCV genotype 1 infection without cirrhosis, the rate of sustained virologic response was 94% with 8 weeks of ledipasvir–sofosbuvir, 93% with 8 weeks of ledipasvir–sofosbuvir plus ribavirin, and 95% with 12 weeks of ledipasvir–sofosbuvir. More than 3 million people in the United States are chronically infected with the hepatitis C virus… Read More…

Keeping up with Novel Hepatitis C Genotype 1 Trials

Posted by • May 14th, 2014

This week’s NEJM features two studies (ION-1 and ION-3) that examine ledipasvir, a NS5A inhibitor, and sofosbuvir, a nucleotide polymerase inhibitor, for previously untreated HCV infection.  A recent search of the New England Journal of Medicine archives for the term “HCV” returned 45 original research articles from the last 5 years. For many of us,… Read More…

Ledipasvir–Sofosbuvir for Previously Treated HCV

Posted by • April 16th, 2014

The old adage, “The more things change, the more they stay the same,” simply does not apply when it comes to the treatment of hepatitis C virus (HCV). The mainstay of HCV treatment for many years has included interferon (peginterferon, since 2001) and ribavirin. While relatively effective for patients with HCV genotypes 2 and 3,… Read More…

HCV-Related Cryoglobulinemic Vasculitis

Posted by • September 13th, 2013

Cryoglobulins are present in about a quarter of patients with hepatitis C; in some, cryoglobulinemia can become symptomatic or even life-threatening. The latest article in our Current Concepts review series summarizes evolving therapy for the disorder, including new therapeutic options that are becoming available. Cryoglobulins are immunoglobulins characterized by their insolubility at low temperatures and their… Read More…

Hepatitis C Virus Infection

Posted by • May 17th, 2013

Only 20 years after the discovery of the hepatitis C virus, a cure is now likely for most people with chronic infection. The latest review in our Drug Therapy series considers current therapy and the present landscape of drug development for hepatitis C. The hepatitis C virus (HCV) carries a substantial disease burden, not only in… Read More…

Treatment of Hepatitis C

Posted by • January 19th, 2012

In a new study of 21 patients with hepatitis C virus genotype 1 infection who had had no response to prior treatment, sustained virologic responses were achieved in 4 of 11 who were treated with two antiviral agents alone and in 9 of 10 who were treated with the antiviral agents plus peginterferon and ribavirin. Approximately… Read More…

Hope for Hepatitis C

Posted by • January 18th, 2012

Imagine, for a moment, that you recently received a brand new Time-O-Matic Time Machine as a gift. How far back would you have to set the dial to see that meaningful progress has been made in the treatment of hepatitis C? First, let’s say you set the dial to January 2011 and –- Puff-kachunk! — you’re… Read More…

Treatment of Hepatitis C

Posted by • April 14th, 2010

Worldwide, an estimated 170 million people have chronic HCV infection, and many will develop cirrhosis and complications of end-stage liver disease. Chronic HCV infection is the leading cause of liver disease and indication for liver transplantation in the United States and Europe. In the Original Article, Telaprevir for Previously Treated Chronic HCV Infection, McHutchison et al…. Read More…